Thoratec downgraded to Neutral from Buy at Goldman Goldman Sachs downgraded Thoratec to Neutral citing the weaker LVAD market and limited visibility following the company's Q2 results. The firm lowered its price target for shares to $28 from $38. Goldman keeps a Sell rating on peer HeartWare (HTWR) and lowered its price target on the name to $73 from $75.
News For THOR;HTWR From The Last 14 Days
Check below for free stories on THOR;HTWR the last two weeks.